Author’s Reply to Srinivas: “Modeling the Relationship Between Exposure to Abiraterone and Prostate-Specific Antigen Dynamics in Patients with Metastatic Castration-Resistant Prostate Cancer”

被引：0
作者：
Steven Xu
Peter De Porre
机构：
[1] Janssen Research & Development,
[2] Janssen Research & Development,undefined
来源：
Clinical Pharmacokinetics | 2017年 / 56卷
关键词：
Abiraterone; Enzalutamide; Abiraterone Acetate; Half Maximal Effective Concentration; mCRPC Patient;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：213 / 214
页数：1
相关论文
共 28 条
  • [1] Srinivas NR(2016)Comment on: “Modeling the relationship between exposure to abiraterone and prostate-specific antigen dynamics in patients with metastatic castration-resistant prostate cancer” Clin Pharmacokinet. 53 1149-1160
  • [2] Stuyckens K(2014)Population pharmacokinetic analysis of abiraterone in chemotherapy-naive and docetaxel-treated patients with metastatic castration-resistant prostate cancer Clin Pharmacokinet. 26 4563-4571
  • [3] Saad F(2008)Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven J Clin Oncol. 28 1481-1488
  • [4] Xu XS(2010)Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy J Clin Oncol. 28 1489-1495
  • [5] Attard G(2010)Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate J Clin Oncol. 28 1496-1501
  • [6] Reid AHM(2010)Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer J Clin Oncol. 13 983-992
  • [7] Yap TA(2012)Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study Lancet Oncol. 16 152-160
  • [8] Ryan CJ(2015)Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study Lancet Oncol. 14 3213-3214
  • [9] Smith MR(2015)Clinical significance of D4A in prostate cancer therapy with abiraterone Cell Cycle. 523 347-351
  • [10] Fong L(2015)Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer Nature. undefined undefined-undefined
123